Soft drinks can cause obesity, tooth wear: Study

Agencies
October 28, 2019

London, Oct 28: The consumption of sugar-sweetened acidic drinks -- such as soft drinks -- is the common factor connecting obesity and tooth wear among adults, according to a study which suggests that dentists should be concerned about the calories their patients get from carbonated beverages.

The researchers, including those from King's College London, found that being overweight, or obese, was strongly associated with having worn out teeth.

The findings of the study, published in the journal Clinical Oral Investigation, suggests that the increased consumption of sugary soft drinks by obese patients may be the leading cause of the erosion of the tooth enamel, and dentine -- the hard bony structure forming the bulk of a tooth.

The researchers analysed a sample of survey participants of 3,541 patients in the United States based on data from the National Health and Nutrition Examination Survey 2003-2004.

For the study, the researchers took into account patient BMI, their intake of sugar-sweetened acidic drinks, and their levels of tooth wear.

"It is the acidic nature of some drinks such as carbonated drinks and acidic fruit juices that leads to tooth wear," said lead author Saoirse O'Toole from King's College London.

According to the researchers, tooth wear ranked as the third most important dental condition -- after cavities and gum disease -- and its leading cause is the consumption of acidic foods and drinks.

"This is an important message for obese patients who are consuming calories through acidic sugar-sweetened drinks. These drinks may be doing damage to their body and their teeth," O'Toole said.

The researchers said that changing consumption habits can help patients prevent tooth wear, or at least stop it before it gets worse.

"There is also an important message for dentists. We should be asking our patients who are obese and have tooth wear what calories they are drinking as this may be having an effect on their full bodies - not just their teeth," O'Toole said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
September 19,2020

mask.JPG

New Delhi, Sept 19: Scientists examined the effectiveness of common household fabrics used in homemade masks in blocking droplets generated by coughing and sneezing, and have found that they are considerably protective even as a single layer.

While earlier studies have focussed on the transfer of tiny, nanoscale aerosol particles through masks, the researchers from the University of Illinois at Urbana-Champaign in the US said speaking, coughing, and sneezing generates larger droplets -- about one millimeter in diameter -- that can carry virus particles.

They said the larger droplets pose a problem as they can squeeze through the pores of some fabrics if they have sufficient momentum, and break into smaller droplets and become airborne.

In the study, published in the journal Extreme Mechanics Letters, the scientists filled the nozzle of an inhaler with distilled water seeded with easy-to-find ultrasmall fluorescent particles -- which happens to be the size of a novel coronavirus particle.

The inhaler forced the water through the nozzle when puffed, and generated high-momentum droplets that collected on a plastic dish placed in front of the inhaler, the study noted.

The researchers repeated this process with the various materials placed over the collection dishes to test their ability to block the particles.

"We count the number of nanoparticles landing on the dish using a high-resolution confocal microscope. We can then use the ratio of the number collected with and without the fabric to give us a measure of droplet-blocking efficiency," said study co-author Taher Saif.

However, the scientists said for an individual to feel compelled to wear a mask, the material must not only be able to block the droplets, but also be comfortable and breathable.

"A mask made out of a low-breathability fabric is not only uncomfortable, but can also result in leakage as the exhaled air is forced out around contours of a face, defeating the purpose of the mask and providing a false sense of protection," Saif said.

"Our goal is to show that many common fabrics exploit the trade-off between breathability and efficiency of blocking droplets -- large and small," he added.

The scientists tested the breathability and droplet-blocking ability of 11 common household fabrics, including new and used garments, quilted cloths, bedsheets and dishcloth material, using a medical mask as a benchmark.

They then characterised the fabrics in terms of their construction, fiber content, weight, thread count, porosity and water-absorption rate.

Their analyses revealed that droplets leave the inhaler at about 17 metres per second (mps) while those released by speaking, coughing and sneezing have velocities within the range of 10 to 40 (mps).

"We found that all of the fabrics tested are considerably effective at blocking the 100 nanometer particles carried by high-velocity droplets similar to those that may be released by speaking, coughing and sneezing, even as a single layer," Saif said.

"With two or three layers, even the more permeable fabrics, such as T-shirt cloth, achieve droplet-blocking efficiency that is similar to that of a medical mask, while still maintaining comparable or better breathability," he added.

The researchers believe the new experimental platform may offer a way to test fabrics for their blocking efficiency against the small and larger droplets that are released as people breathe, or cough.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
September 25,2020

A standard test that assesses blood cells can identify which patients admitted to hospital with COVID-19 could face a high risk of becoming critical and die, say researchers.

"We wanted to help find ways to identify high-risk COVID patients as early and as easily as possible -- who are likely to become severely ill and which hospitalized patients are likely to get worse quickly," said study researcher John M Higgins from the Massachusetts General Hospital in the US.

Higgins noted that early reports from China indicated that the body's inflammatory response was extremely intense in some patients and very mild in others.

His own group's previous work revealed that certain changes in the numbers and types of blood cells during inflammation are associated with poor health outcomes in patients with diseases such as heart disease, cancer, and diabetes.

"We quickly re-focused our computational infrastructure towards the analysis of the Covid-19 patient cohort that was growing rapidly in the Boston area last spring," explained study first author Brody Foy from the Harvard Medical School.

Their analysis, published in the journal JAMA Network Open, included all adults diagnosed with SARS-CoV-2 infection and admitted to one of four hospitals in the Boston area between March 4 and April 28, 2020.

Before looking for complicated changes in circulating blood cells in the 1,641 patients included in the study, the scientists first searched for patterns using currently available blood tests that are routinely performed.

"We were surprised to find that one standard test that quantifies the variation in size of red blood cells -- called red cell distribution width, or RDW -- was highly correlated with patient mortality," the researchers wrote.

The correlation persisted when controlling for other identified risk factors like patient age, some other lab tests, and some pre-existing illnesses," they added.

Patients who had RDW values above the normal range when they were admitted to the hospital had a 2.7-times higher risk of dying, with a mortality rate of 31 per cent compared with 11 per cent in patients with normal RDW values.

Also, a subsequent increase in RDW after admission was associated with an even higher risk of dying, indicating that RDW could be tracked during hospitalization to help determine whether patients are responding to treatment or getting worse.

The investigators are currently seeking to uncover the mechanisms that cause RDW elevations in severe COVID-19 cases.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
September 29,2020

Pune, Sept 29: A further collaboration among the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective COVID-19 vaccines for India and low-and middle income countries.

This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August.

The arrangement again provides an option to secure additional doses if the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator sees a need for it. The collaboration will provide upfront capital to SII to help it increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be distributed at scale to LMICs as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.

"The collaboration further bolsters our fight against COVID-19. Through the avid support of Gavi and the Bill & Melinda Gates Foundation, we will now manufacture and deliver up to an additional 100 million doses of immunogenic and safe-proven future Covid-19 vaccines to India and low- and middle-income countries in 2021," said Adar Poonawalla, CEO of Serum Institute of India.

He added, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that the future vaccines reach the remotest part of the world providing full immunization coverage in a bid to contain the spread of the pandemic."

The funding will help accelerate the manufacturing by SII for candidate vaccines licensed from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification.

The vaccines will have a ceiling price of US$3 per dose, a price enabled by investments made by partners such as the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill and Melinda Gates Foundation and SII. "This is vaccine manufacturing for the Global South, by the Global South, helping us to ensure no country is left behind when it comes to access to a Covid-19 vaccine," said Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance.

"The momentum behind our effort to ensure global, equitable access to Covid-19 vaccines is really building. Last week, we were able to announce the historic number of countries that are now signed up to the COVAX Facility, today we can announce further doses of safe, effective vaccines that will be reserved specifically for low- and middle-income countries. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines; this collaboration brings us another step closer to achieving this goal."

The Gavi COVAX AMC, which is currently seeking at least US$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine doses. The Gavi Board has agreed upon the final list of 92 countries that will be supported by the Gavi COVAX AMC. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries.

Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi COVAX AMC. These countries align with SII's licensing agreements with the two partners. The collaboration between Gavi, SII, and the Gates Foundation supports the efforts of the ACT Accelerator's vaccines pillar, also known as COVAX, co-led by Gavi, CEPI and the World Health Organization (WHO), to accelerate the development of COVID-19 vaccines and ensure rapid, global access to them.

Decisions around investment in manufacturing are taken in close collaboration between these three lead organisations of the COVAX pillar. Under the COVAX umbrella, Gavi is coordinating the COVAX Facility, which provides governments with the opportunity to benefit from a large portfolio of Covid-19 candidate vaccines using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand.

So far 73 higher-income economies have formally committed to join the Facility, in addition to the 92 low- and middle-income economies that are eligible for support from the Gavi COVAX AMC. The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further US$150 million to Gavi, bringing the total funding provided through this collaboration to US$300 million.

This will be used to support the Serum Institute of India to manufacture potential vaccine candidates, and for future procurement of vaccines for India and low- and middle-income countries via Gavi's COVAX AMC.

The deal is additional to a Memorandum of Understanding between AstraZeneca and Gavi, announced in June, which will commit an additional 300 million doses of AstraZeneca's candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification. These two deals can help assure access to early doses for the most vulnerable on a truly global scale.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.